Can Cannabis Help with Multiple Sclerosis Symptoms? What MS Patients Need to Know

Nearly 130,000 people in the UK live with multiple sclerosis, making it one of the most common neurological conditions. However, up to 84% of MS patients experience debilitating spasticity that often remains poorly controlled despite conventional treatments.

Understanding Multiple Sclerosis and the Endocannabinoid System

Multiple sclerosis is a chronic autoimmune condition where the body’s immune system attacks the protective myelin sheaths surrounding nerve fibres. Consequently, this creates inflammation, scarring, and disrupted nerve signals throughout the central nervous system.

Interestingly, researchers have discovered that the endocannabinoid system plays a crucial role in MS pathology. Specifically, CB1 receptors in the brain and spinal cord help regulate muscle tone and pain signalling. Meanwhile, CB2 receptors on immune cells modulate the inflammatory response that drives MS progression.

In addition, the body’s natural endocannabinoids — anandamide and 2-AG — become depleted in MS patients. As a result, this creates an opportunity for plant-based cannabinoids to restore balance and potentially alleviate symptoms.

Clinical Evidence for Cannabis in Multiple Sclerosis

The strongest evidence for medical cannabis in MS centres on spasticity management. For example, Sativex (nabiximols) has undergone extensive clinical trials using a unique “enrichment” design. Initially, all patients receive the medication for four weeks, then only those showing at least 20% improvement continue to the randomised phase.

However, results from these trials demonstrate that 40-70% of MS patients experience meaningful spasticity reduction. In addition, patients report improvements in painful muscle spasms, sleep quality, and bladder function. That said, the evidence base remains limited for other MS symptoms like fatigue and cognitive issues.

Furthermore, recent studies suggest cannabis multiple sclerosis treatment may offer neuroprotective benefits. Specifically, CBD appears to reduce inflammation and oxidative stress in neural tissue. Nevertheless, more research is needed to confirm whether medical cannabis can slow disease progression.

Cannabinoid Profiles Most Studied in MS Research

Most clinical trials in MS have focused on balanced THC:CBD formulations, particularly the 1:1 ratio found in Sativex. Specifically, each spray delivers 2.7mg THC and 2.5mg CBD, providing both symptom relief and fewer psychoactive side effects.

For example, THC primarily targets CB1 receptors to reduce spasticity and central pain. Meanwhile, CBD modulates inflammation through CB2 receptors and other pathways. Importantly, CBD also counteracts some of THC’s intoxicating effects, making daytime use more tolerable.

However, some patients benefit from higher THC ratios (2:1 or 3:1) for severe spasticity or neuropathic pain. Conversely, others prefer CBD-dominant formulations (1:2 or 1:4) to minimise cognitive impairment while maintaining anti-inflammatory benefits.

In addition, emerging research explores specific terpenes like myrcene for muscle relaxation and beta-caryophyllene for inflammation. Nevertheless, most current prescriptions focus on standardised THC:CBD ratios rather than terpene profiles.

Routes of Administration and Dosing Considerations

Medical cannabis for MS is typically prescribed as oromucosal sprays, oral oils, or capsules. Importantly, these routes avoid the respiratory risks associated with smoking while providing controlled, measurable dosing.

Sativex remains the gold standard, with patients typically starting at one spray daily and gradually increasing to 4-8 sprays per day. However, some patients require up to 12 sprays daily for optimal symptom control. In addition, the spray format allows for flexible dosing throughout the day.

For example, many patients use lower doses during daytime hours to maintain function, then increase evening doses for sleep and overnight spasticity. Meanwhile, oils and capsules provide longer-lasting effects but less dosing flexibility.

That said, individual response varies significantly. Consequently, careful titration under specialist supervision remains essential for optimising benefits while minimising side effects.

Cannabis Multiple Sclerosis Treatment: Patient Selection and Safety

Medical cannabis isn’t suitable for all MS patients. Specifically, those with active psychosis, severe cardiovascular disease, or substance use disorders should avoid THC-containing treatments. In addition, pregnancy and breastfeeding represent absolute contraindications.

Furthermore, cannabis can interact with certain medications commonly used in MS. For example, it may enhance the sedative effects of baclofen or gabapentin. Meanwhile, it can potentially interfere with some disease-modifying therapies, though significant interactions are rare.

However, most MS patients tolerate medical cannabis well when properly supervised. Common side effects include dizziness, fatigue, and dry mouth, particularly during initial titration. Importantly, these effects usually diminish with continued use and dose adjustment.

Moreover, cognitive effects represent a key concern for many patients. Consequently, starting with low doses and avoiding daytime use initially helps maintain work and social function while assessing individual tolerance.

Integration with Conventional MS Treatments

Medical cannabis works best as adjunctive therapy alongside established MS treatments. Importantly, it doesn’t replace disease-modifying therapies that slow MS progression. Instead, it addresses symptomatic burden that conventional treatments often struggle to control.

For example, many patients continue using baclofen, tizanidine, or gabapentin while adding medical cannabis. However, dosage adjustments of existing medications may be necessary to avoid excessive sedation or other interactions.

In addition, physiotherapy and occupational therapy remain crucial components of comprehensive MS care. Interestingly, some patients find cannabis enhances their ability to participate in rehabilitation by reducing spasticity and pain during exercise sessions.

Nevertheless, open communication between all healthcare providers ensures safe, coordinated care. Specifically, neurologists, cannabis specialists, and other team members should collaborate to optimise treatment outcomes.

Accessing Cannabis Multiple Sclerosis Treatment in the UK

Medical cannabis for MS is available through private prescription from doctors on the GMC Specialist Register. Importantly, recreational use remains illegal, and patients must obtain cannabis through licensed medical channels only.

Currently, NHS funding covers Sativex for MS spasticity in some cases, though access varies across different regions. However, most patients seek private treatment through specialist clinics that focus on medical cannabis prescribing.

For example, eligibility typically requires evidence of trying at least two conventional treatments without adequate symptom control. In addition, patients need documented MS diagnosis and specific symptoms that cannabis may help address.

That said, private treatment costs can be significant, with monthly expenses ranging from £200-800 depending on dosage and product choice. Consequently, discussing treatment goals and financial considerations with prescribing doctors helps ensure sustainable long-term therapy.

_This article is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting any new supplement or medication, especially if you have underlying health conditions._